Loganathan Aravinthan, Raman Arupam, Berlinski Natalia, Riordan John
Rheumatology Department, Wollongong Hospital, NSW Health, Wollongong, NSW, Australia.
Clin Med Insights Arthritis Musculoskelet Disord. 2022 May 23;15:11795441221097351. doi: 10.1177/11795441221097351. eCollection 2022.
The estimated prevalence of gout in Western societies is 2.7% to 6.7%. In Australia, there have been increasing rates of hospitalisations for gout flares. Urate-lowering therapy (ULT) is effective in reducing urate burden, which can prevent gout flares and destructive arthropathy. This study assessed the representation rate of patients presenting to the Emergency Department (ED) with crystal arthropathy and the utilisation of ULT in the community for patients with a pre-existing history of gout.
A retrospective review of electronic records of patients presenting to the ED from the Illawarra Shoalhaven Local Health District was performed. Patients included were coded as per the 10th revision of the International Classification of Diseases coding for crystal arthropathy.
In all, 18.8% of all crystal arthropathy encounters to the ED were repeat presentations. Of the 70% of patients with a history of gout, only 30.8% were on ULT.
Despite evidence-based recommendations for a 'treat-to-target' approach, most patients with a previous history of gout were not on ULT. One in five encounters were re-presentations for crystal arthropathy. Effective adherence to treatment guidelines may reduce the number of repeat encounters for gout flare in the ED.
西方社会痛风的估计患病率为2.7%至6.7%。在澳大利亚,痛风发作的住院率一直在上升。降尿酸治疗(ULT)在减轻尿酸负担方面有效,可预防痛风发作和破坏性关节病。本研究评估了因晶体性关节病到急诊科(ED)就诊的患者比例,以及社区中已有痛风病史患者的ULT使用情况。
对来自伊拉瓦拉-肖尔黑文地方卫生区到急诊科就诊患者的电子记录进行回顾性分析。纳入的患者根据国际疾病分类第10版编码为晶体性关节病。
在所有到急诊科就诊的晶体性关节病病例中,18.8%为复诊。在有痛风病史的患者中,仅30.8%接受ULT治疗。
尽管有基于证据的“达标治疗”方法建议,但大多数有痛风病史的患者未接受ULT治疗。五分之一的就诊是因晶体性关节病复诊。有效遵循治疗指南可能会减少急诊科痛风发作的复诊次数。